{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:28:35Z","timestamp":1793212115307,"version":"4.5.0"},"reference-count":88,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","semarthritisrheumatism.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.semarthrit.2016.01.001","type":"journal-article","created":{"date-parts":[[2016,1,21]],"date-time":"2016-01-21T16:52:03Z","timestamp":1453395123000},"page":"S1-S10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"S","title":["Biosimilars: Rationale and current regulatory landscape"],"prefix":"10.1016","volume":"45","author":[{"given":"Ewa","family":"Olech","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2016.01.001_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar3310","article-title":"Biosimilars: a regulatory perspective from America","volume":"13","author":"Kay","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2016.01.001_bib2","first-page":"57","article-title":"Understanding and incentivizing biosimilars","volume":"64","author":"Kanter","year":"2012","journal-title":"Hastings Law J"},{"key":"10.1016\/j.semarthrit.2016.01.001_bib3","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/annrheumdis-2012-202715","article-title":"The role of biosimilars in the treatment of rheumatic diseases","volume":"72","author":"D\u00f6rner","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.01.001_bib4","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1126\/science.6337396","article-title":"Human insulin from recombinant DNA technology","volume":"219","author":"Johnson","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.semarthrit.2016.01.001_bib5","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/btpr.2066","article-title":"Biosimilars advancements: moving on to the future","volume":"31","author":"Tsuruta","year":"2015","journal-title":"Biotechnol Prog"},{"key":"10.1016\/j.semarthrit.2016.01.001_bib6","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nm.3260","article-title":"How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy","volume":"19","author":"Schett","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.semarthrit.2016.01.001_bib7","first-page":"294","article-title":"Biosimilars: a systematic review of published and ongoing clinical trials of antipsoriatics in chronic inflammatory diseases","volume":"13","author":"Nast","year":"2015","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.semarthrit.2016.01.001_bib8","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1177\/1756283X14558193","article-title":"Current, new, and future biological agents on the horizon for the treatment of inflammatory bowel diseases","volume":"8","author":"Amiot","year":"2015","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.semarthrit.2016.01.001_bib9","series-title":"Targeted treatment of the rheumatic diseases","article-title":"Introduction of a biologic agent into the clinic","author":"Strand","year":"2010"},{"key":"10.1016\/j.semarthrit.2016.01.001_bib10","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/nrrheum.2012.84","article-title":"The advent of biosimilar therapies in rheumatology\u2014\u201cO Brave New World\u201d","volume":"8","author":"Scheinberg","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.01.001_bib11","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.01.001_bib12","first-page":"S3","article-title":"Core management principles in rheumatoid arthritis to help guide managed care professionals","volume":"17","author":"Agarwal","year":"2011","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.semarthrit.2016.01.001_bib13","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2016.01.001_bib14","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ajg.2008.168","article-title":"Practice parameters committee of American College of gastroenterology. Management of Crohn\u2019s disease in adults","volume":"104","author":"Lichtenstein","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.semarthrit.2016.01.001_bib15","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/ajg.2009.727","article-title":"Practice parameters committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee","volume":"105","author":"Kornbluth","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.semarthrit.2016.01.001_bib16","first-page":"353","article-title":"On the regulatory approval pathway of biosimilar products","volume":"5","author":"Wang","year":"2012"},{"key":"10.1016\/j.semarthrit.2016.01.001_bib17","unstructured":"European Medicines Agency. European public assessment reports-biosimilars, \u3008http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/landing\/epar_search.jsp&mid=WC0b01ac058001d124&searchTab=searchByAuthType&keyword=Enter keywords&searchType=name&alreadyLoaded=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&jsenabled=false&searchGenericType=biosimilars&orderBy=authDate&pageNo=1\u3009 [accessed 22.10.15]."},{"key":"10.1016\/j.semarthrit.2016.01.001_bib18","doi-asserted-by":"crossref","first-page":"132","DOI":"10.5639\/gabij.2012.0103-4.023","article-title":"Terminology for biosimilars\u2014a confusing minefield","volume":"1","author":"Thorpe","year":"2012","journal-title":"GaBI J"},{"key":"10.1016\/j.semarthrit.2016.01.001_bib19","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/nbt.1936","article-title":"Biosimilars\u2014why terminology matters","volume":"29","author":"Weise","year":"2011","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.semarthrit.2016.01.001_bib20","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products, \u3008http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2014\/10\/WC500176768.pdf\u3009; 2014 [accessed 15.06.15]."},{"key":"10.1016\/j.semarthrit.2016.01.001_bib21","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrd2307","article-title":"The FDA\u2019s assessment of follow-on protein products: a historical perspective","volume":"6","author":"Woodcock","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.semarthrit.2016.01.001_bib22","unstructured":"U.S. Food and Drug Administration. Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product, \u3008http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm291128.pdf\u3009; 2015 [accessed 15.06.15]."},{"key":"10.1016\/j.semarthrit.2016.01.001_bib23","unstructured":"Health Canada. Guidance for sponsors: information and submission requirements for Subsequent Entry Biologics (SEBs) Minister of Public Works and Government Services Canada, \u3008http:\/\/www.hc-sc.gc.ca\/dhp-mps\/alt_formats\/pdf\/brgtherap\/applic-demande\/guides\/seb-pbu\/seb-pbu-2010-eng.pdf\u3009; 2010 [accessed 30.06.15]."},{"key":"10.1016\/j.semarthrit.2016.01.001_bib24","first-page":"83","article-title":"Mexico recovers leadership on regulation of biosimilar biotech drugs","volume":"148","author":"L\u00f3pez Silva","year":"2012","journal-title":"Gac Med Mex"},{"key":"10.1016\/j.semarthrit.2016.01.001_bib25","unstructured":"World Health Organization. Guidelines on evaluation of similar biotherapeutic products (SBPs), \u3008http:\/\/www.who.int\/biologicals\/areas\/biological_therapeutics\/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf\u3009; 2009 [accessed 15.06.15]."},{"key":"10.1016\/j.semarthrit.2016.01.001_bib26","series-title":"The precarious struggle between cost-driven health care policy and patient-centered care","article-title":"Biosimilars","author":"Pitts","year":"2012"},{"key":"10.1016\/j.semarthrit.2016.01.001_bib27","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4161\/mabs.3.2.14785","article-title":"Biosimilar, biobetter and next generation therapeutic antibodies","volume":"3","author":"Beck","year":"2011","journal-title":"MAbs"},{"key":"10.1016\/j.semarthrit.2016.01.001_bib28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40258-015-0154-9","article-title":"Biosimilar versus generic drugs: same but different","volume":"13","author":"Van de Vooren","year":"2015","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.semarthrit.2016.01.001_bib29","unstructured":"International Federation of Pharmaceutical Manufacturers & Associations. Noncomparable biotherapeutic products: policy statement, \u3008http:\/\/www.ifpma.org\/uploads\/media\/Non-comparable_Biotherapeutic_Products__English__06.pdf\u3009; 2014 [accessed 30.06.15]."},{"key":"10.1016\/j.semarthrit.2016.01.001_bib30","first-page":"20","article-title":"A biologic by any other name","volume":"7","author":"Strand","year":"2013","journal-title":"Rheumatologist"},{"issue":"6","key":"10.1016\/j.semarthrit.2016.01.001_bib31","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1186\/s13075-014-0501-5","article-title":"Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice","volume":"16","author":"Scheinberg","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2016.01.001_bib32","unstructured":"Barile-Fabris L, Irazoque-Palazuelos F, Hern\u00e1ndez V\u00e1squez R, Carrillo Vazquez S, Guzman R. Incidence of adverse events in patients treated with intended copies of biologic therapeutic agents in Colombia and Mexico. Poster 1506. American College of Rheumatology Annual Meeting; 2014."},{"key":"10.1016\/j.semarthrit.2016.01.001_bib33","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1177\/0300985814547282","article-title":"Frontiers in nonclinical drug development: biosimilars","volume":"52","author":"Ryan","year":"2015","journal-title":"Vet Pathol"},{"key":"10.1016\/j.semarthrit.2016.01.001_bib34","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1136\/gutjnl-2012-303824","article-title":"Biosimilars in IBD: hope or expectation","volume":"62","author":"Gecse","year":"2013","journal-title":"Gut"},{"issue":"Suppl. 1","key":"10.1016\/j.semarthrit.2016.01.001_bib35","doi-asserted-by":"crossref","first-page":"i27","DOI":"10.1093\/ndtplus\/sfn177","article-title":"Biosimilar therapeutics-what do we need to consider?","volume":"2","author":"Schellekens","year":"2009","journal-title":"NDT Plus"},{"key":"10.1016\/j.semarthrit.2016.01.001_bib36","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10637-012-9899-2","article-title":"Clinical trial design in biosimilar drug development","volume":"31","author":"Dranitsaris","year":"2013","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.semarthrit.2016.01.001_bib37","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1517\/14712598.2012.758710","article-title":"Biosimilar monoclonal antibodies: a science-based regulatory challenge","volume":"13","author":"Declerck","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.semarthrit.2016.01.001_bib38","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues, \u3008http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2015\/01\/WC500180219.pdf\u3009; 2014 [accessed 28.07.15]."},{"key":"10.1016\/j.semarthrit.2016.01.001_bib39","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products containing monoclonal antibodies\u2014non-clinical and clinical issues, \u3008http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/06\/WC500128686.pdf\u3009; 2012 [accessed 15.06.15]."},{"key":"10.1016\/j.semarthrit.2016.01.001_bib40","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1182\/blood-2012-04-425744","article-title":"Biosimilars: what clinicians should know","volume":"120","author":"Weise","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2016.01.001_bib41","unstructured":"Wroblewski MS, Jex EA, Munck SD, Garmon CJ, Michel ST, Wantman A, et al. Emerging health care issues: follow-on biologic drug competition. US Federal Trade Commission, \u3008http:\/\/www.ftc.gov\/sites\/default\/files\/documents\/reports\/emerging-health-care-issues-follow-biologic-drug-competition-federal-trade-commission-report\/p083901biologicsreport.pdf\u3009; 2009 [accessed 15.06.15]."},{"key":"10.1016\/j.semarthrit.2016.01.001_bib42","first-page":"22","article-title":"CMO perspective on quality challenges for biopharmaceuticals","volume":"11","author":"Gupta","year":"2013","journal-title":"BioProcess Int"},{"key":"10.1016\/j.semarthrit.2016.01.001_bib43","unstructured":"US Food and Drug Administration. Guidance for industry: clinical development programs for drugs, devices, and biological products for the treatment of rheumatoid arthritis (RA), \u3008http:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/ucm071579.pdf\u3009; 1999 [accessed 15.06.15]."},{"key":"10.1016\/j.semarthrit.2016.01.001_bib44","unstructured":"U.S. Food and Drug Administration. Draft guidance for industry: reference product exclusivity for biological products filed under section 351(a) of the PHS Act, \u3008http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm407844.pdf\u3009; 2014 [accessed 15.06.15]."},{"key":"10.1016\/j.semarthrit.2016.01.001_bib45","unstructured":"US Food and Drug Administration. Guidance for industry: quality considerations in demonstrating biosimilarity to a reference protein product, \u3008http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm291134.pdf\u3009; 2015 [accessed 15.06.15]."},{"key":"10.1016\/j.semarthrit.2016.01.001_bib46","unstructured":"US Food and Drug Administration. Draft guidance for industry: biosimilars: questions and answers regarding implementation of the Biologics Price Competition and Innovation Act of 2009, \u3008http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM273001.pdf\u3009; revised May 2015 [accessed 15.06.15]."},{"key":"10.1016\/j.semarthrit.2016.01.001_bib47","unstructured":"US Food and Drug Administration. Guidance for industry: biosimilars: additional questions and answers regarding implementation of the Biologics Price Competition and Innovation Act of 2009, \u3008http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM444661.pdf\u3009; 2015 [accessed 15.06.15]."},{"issue":"Suppl. 6","key":"10.1016\/j.semarthrit.2016.01.001_bib48","first-page":"s24","article-title":"Biosimilars awaken CROs","volume":"12","author":"Galbraith","year":"2014","journal-title":"BioProcess Int"},{"key":"10.1016\/j.semarthrit.2016.01.001_bib49","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/clpt.2011.343","article-title":"The state of the art in the development of biosimilars","volume":"91","author":"McCamish","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.semarthrit.2016.01.001_bib50","unstructured":"Congress of the United States of America. Biologics Price Competition and Innovation Act, \u3008http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/UCM216146.pdf\u3009; 2009 [accessed 15.06.15]."},{"key":"10.1016\/j.semarthrit.2016.01.001_bib51","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/imj.12292","article-title":"Biosimilars: how similar","volume":"44","author":"Strand","year":"2014","journal-title":"Intern Med J"},{"key":"10.1016\/j.semarthrit.2016.01.001_bib52","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products, \u3008http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003517.pdf\u3009; 2005 [accessed 15.06.15]."},{"key":"10.1016\/j.semarthrit.2016.01.001_bib53","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1), \u3008http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2014\/06\/WC500167838.pdf\u3009; 2014 [accessed 15.06.15]."},{"key":"10.1016\/j.semarthrit.2016.01.001_bib54","unstructured":"European Medicines Agency. Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use, \u3008http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/06\/WC500128688.pdf\u3009; 2012 [accessed 15.06.15]."},{"key":"10.1016\/j.semarthrit.2016.01.001_bib55","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.4161\/mabs.29848","article-title":"Biosimilars entering the clinic without animal studies: a paradigm shift in the European Union","volume":"6","author":"Van Aerts","year":"2014","journal-title":"MAbs"},{"key":"10.1016\/j.semarthrit.2016.01.001_bib56","unstructured":"European Generic Medicines Association. Biosimilars handbook, \u3008http:\/\/www.egagenerics.com\/images\/Website\/EGA_BIOSIMILARS_handbook_en.pdf\u3009 [accessed 15.06.15]."},{"key":"10.1016\/j.semarthrit.2016.01.001_bib57","unstructured":"Rovira J, Esp\u00edn J, Garc\u00eda L, Olry de Labry A. The impact of biosimilars\u2019 entry in the EU market, \u3008http:\/\/ec.europa.eu\/DocsRoom\/documents\/7651\/attachments\/1\/translations\/en\/renditions\/pdf\u3009; 2011 [accessed 12.02.16]."},{"key":"10.1016\/j.semarthrit.2016.01.001_bib58","unstructured":"Netherlands Medicines Evaluation Board. News item. Clarification of stance on biological and biosimilar medicines, \u3008http:\/\/english.cbg-meb.nl\/latest\/news\/2015\/08\/17\/clarification-of-stance-on-biological-and-biosimilar-medicines\u3009; 17.08.15 [accessed 24.09.15]."},{"key":"10.1016\/j.semarthrit.2016.01.001_bib59","unstructured":"Taylor L. France moving ahead with biosimilar substitution. PharmaTimes Digital, \u3008http:\/\/www.pharmatimes.com\/Article\/14-04-13\/France_moving_ahead_with_biosimilar_substitution.aspx\u3009; 2014 [accessed 12.02.16]."},{"issue":"6 Suppl.","key":"10.1016\/j.semarthrit.2016.01.001_bib60","doi-asserted-by":"crossref","first-page":"s16","DOI":"10.1016\/j.semarthrit.2015.04.003","article-title":"Inflammatory diseases: integrating biosimilars into clinical practice","volume":"44","author":"Feldman","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.01.001_bib61","unstructured":"European Medicines Agency. Assessment Report. Tevagrastim, \u3008http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/000827\/WC500036667.pdf\u3009; 2008 [accessed 15.06.15]."},{"key":"10.1016\/j.semarthrit.2016.01.001_bib62","unstructured":"European Medicines Agency. Assessment Report. Accofil, \u3008http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/003956\/WC500176640.pdf\u3009; 2014 [accessed 15.06.15]."},{"key":"10.1016\/j.semarthrit.2016.01.001_bib63","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1182\/blood-2014-06-583617","article-title":"Biosimilars: the science of extrapolation","volume":"124","author":"Weise","year":"2014","journal-title":"Blood"},{"issue":"Suppl. 6","key":"10.1016\/j.semarthrit.2016.01.001_bib64","doi-asserted-by":"crossref","first-page":"s9","DOI":"10.1016\/j.semarthrit.2015.04.005","article-title":"Biosimilar safety factors in clinical practice","volume":"44","author":"Reinisch","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.01.001_bib65","doi-asserted-by":"crossref","first-page":"e594","DOI":"10.1016\/S1470-2045(14)70365-1","article-title":"Regulatory and clinical considerations for biosimilar oncology drugs","volume":"15","author":"Bennett","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semarthrit.2016.01.001_bib66","unstructured":"US Food and Drug Administration. Biosimilars guidances, \u3008http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm290967.htm\u3009; [accessed 15.06.15]."},{"key":"10.1016\/j.semarthrit.2016.01.001_bib67","unstructured":"US Food and Drug Administration. Draft guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product, \u3008http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM291128.pdf\u3009; 2012 [accessed 15.06.15]."},{"key":"10.1016\/j.semarthrit.2016.01.001_bib68","unstructured":"US Food and Drug Administration. Draft guidance for industry: quality considerations in demonstrating biosimilarity to a reference protein product; \u3008http:\/\/www.pitdc.org.tw\/member\/%E5%90%84%E5%9C%8B%E6%B3%95%E8%A6%8F\/USA\/Quality%20Considerations%20in%20%20Demonstrating%20%20Biosimilarity%20to%20a%20Reference%20%20Protein%20Product.pdf\u3009 2012 [accessed 21.10.15]."},{"key":"10.1016\/j.semarthrit.2016.01.001_bib69","unstructured":"US Food and Drug Administration. Draft guidance for industry: clinical pharmacology data to support a demonstration of biosimilarity to a reference product, \u3008http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm397017.pdf\u3009; 2014 [accessed 15.06.15]."},{"key":"10.1016\/j.semarthrit.2016.01.001_bib70","unstructured":"US Food and Drug Administration. Background information: lists of licensed biological products with reference product exclusivity and biosimilarity or interchangeability evaluations (purple book), \u3008http:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/HowDrugsareDevelopedandApproved\/ApprovalApplications\/TherapeuticBiologicApplications\/Biosimilars\/ucm411424.htm\u3009. Updated March 2015 [accessed 15.06.15]."},{"key":"10.1016\/j.semarthrit.2016.01.001_bib71","unstructured":"US Food and Drug Administration. Draft guidance for industry. Biosimilars: Additional questions and answers regarding implementation of the Biologics Price Competition and Innovation Act of 2009, \u3008http:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/UCM273001.pdf\u3009; 2015 [accessed 15.06.15]."},{"key":"10.1016\/j.semarthrit.2016.01.001_bib72","unstructured":"Sandoz Press Release. FDA accepts Sandoz application for biosimilar filgrastim, \u3008http:\/\/www.sandoz.com\/media_center\/press_releases_news\/global_news\/2014_07_24_FDA_accepts_Sandoz_application_for_biosimilar_filgrastim.shtml\u3009; 2014 [accessed 15.06.15]."},{"key":"10.1016\/j.semarthrit.2016.01.001_bib73","unstructured":"Celltrion Press Release. Celltrion files for US FDA approval of Remsima\u00ae, \u3008http:\/\/www.celltrion.com\/en\/company\/notice_view.asp?idx=456&code=ennews&intNowPage=1&menu_num=&align_year=all\u3009; 2014 [accessed 15.06.15]."},{"key":"10.1016\/j.semarthrit.2016.01.001_bib74","unstructured":"US Food and Drug Administration [press release]. FDA approves first biosimilar product Zarxio, \u3008http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm436648.htm\u3009; 2015 [accessed 15.06.15]."},{"key":"10.1016\/j.semarthrit.2016.01.001_bib75","unstructured":"National Conference of State Legislatures. State laws and legislation related to biologic medications and substitution of biosimilars, \u3008http:\/\/www.ncsl.org\/documents\/health\/Biologics_BiosimilarsNCSLReport_July_2014.pdf\u3009; 2014 [accessed 15.06.15]."},{"key":"10.1016\/j.semarthrit.2016.01.001_bib76","unstructured":"US Food and Drug Administration. Center for drug evaluation and research summary minutes of the Oncologic Drugs Advisory Committee Meeting January 7, 2015, \u3008http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/OncologicDrugsAdvisoryCommittee\/UCM436385.pdf\u3009; Published January 2015 [accessed 24.09.15]."},{"key":"10.1016\/j.semarthrit.2016.01.001_bib77","unstructured":"ZARXIO\u2122 (filgrastim-sndz) Full Prescribing Information. Princeton, NJ: Sandoz Inc."},{"key":"10.1016\/j.semarthrit.2016.01.001_bib78","unstructured":"US Food and Drug Administration. Guidance for industry: good pharmacovigilance practices and pharmacoepidemiologic assessment, \u3008http:\/\/www.fda.gov\/downloads\/RegulatoryInformation\/Guidances\/UCM126834.pdf\u3009; 2005 [accessed 15.06.15]."},{"key":"10.1016\/j.semarthrit.2016.01.001_bib79","doi-asserted-by":"crossref","first-page":"23","DOI":"10.18553\/jmcp.2015.21.1.23","article-title":"For the AMCP Task Force on Biosimilar Collective Intelligence Systems. Utilizing data consortia to monitor safety and effectiveness of biosimilars and their innovator products","volume":"21","author":"Baldziki","year":"2015","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.semarthrit.2016.01.001_bib80","doi-asserted-by":"crossref","first-page":"36","DOI":"10.5639\/gabij.2014.0401.012","article-title":"Comparison of biosimilars guidelines","volume":"3","author":"Derbyshire","year":"2014","journal-title":"GaBI J"},{"key":"10.1016\/j.semarthrit.2016.01.001_bib81","doi-asserted-by":"crossref","first-page":"41","DOI":"10.12665\/J124.Rader","article-title":"Biosimilars in the rest of the world: developments in lesser-regulated countries","volume":"12","author":"Rader","year":"2014","journal-title":"BioProcess J"},{"key":"10.1016\/j.semarthrit.2016.01.001_bib82","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jbspin.2014.03.019","article-title":"Biopharmaceuticals for rheumatic diseases in Latin America, Europe, Russia, and India: innovators, biosimilars, and intended copies","volume":"81","author":"Casta\u00f1eda-Hern\u00e1ndez","year":"2014","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.semarthrit.2016.01.001_bib83","doi-asserted-by":"crossref","first-page":"143","DOI":"10.5639\/gabij.2014.0303.032","article-title":"Recommendations for the regulation of biosimilars and their implementation in Latin America","volume":"3","author":"Azevedo","year":"2014","journal-title":"GaBI J"},{"key":"10.1016\/j.semarthrit.2016.01.001_bib84","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s10067-015-2887-0","article-title":"Recommendations on how to ensure the safety and effectiveness of biosimilars in Latin America: a point of view","volume":"34","author":"Pineda","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.01.001_bib85","unstructured":"National Institutes of Health. Methotrexate. Pub Chem Compound Summary for CID 126941, \u3008https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/methotrexate#section=Top\u3009 [accessed 01.07.15]."},{"key":"10.1016\/j.semarthrit.2016.01.001_bib86","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1056\/NEJMp1107285","article-title":"Developing the nation\u2019s biosimilars program","volume":"365","author":"Kozlowski","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2016.01.001_bib87","unstructured":"US Government Publishing Office. 42 U.S.C. 262\u2014Regulation of biological products. \u3008http:\/\/www.gpo.gov\/fdsys\/pkg\/USCODE-2010-title42\/pdf\/USCODE-2010-title42-chap6A-subchapII-partF-subpart1-sec262.pdf\u3009 [accessed 25.09.15]."},{"key":"10.1016\/j.semarthrit.2016.01.001_bib88","unstructured":"US Government Publishing Office. 21 U.S.C. 355\u2014New drugs, \u3008http:\/\/www.gpo.gov\/fdsys\/pkg\/USCODE-2010-title21\/pdf\/USCODE-2010-title21-chap9-subchapV-partA-sec355.pdf\u3009 [accessed 25.09.15]."}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017216000275?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017216000275?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,15]],"date-time":"2018-09-15T22:23:48Z","timestamp":1537050228000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017216000275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":88,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0049017216000275"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2016.01.001","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biosimilars: Rationale and current regulatory landscape","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2016.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}